Navigation Links
Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin
Date:1/12/2009

Research and Development for Sunesis. "Our combination study has shown complete remissions and a manageable safety profile. Both studies are continuing to enroll well, and, pending final clinical data, allow us to explore potential registration strategies in either newly diagnosed or first relapse AML populations."

Phase 2 Trial of Voreloxin in Platinum-Resistant Ovarian Cancer

Enrollment is complete for the Phase 2 study of voreloxin in platinum-resistant ovarian cancer. Three schedules of voreloxin have been studied, 48 mg/m2 given every three weeks (N=65), and 60 mg/m2 (N=37) and 75 mg/m2 (N=35) given every four weeks. As reported at the 12th Biennial Meeting International Gynecologic Cancer Society, two complete responses and five partial responses were observed at 48 mg/m2. Thirty patients (46%) achieved disease control, defined as stable disease for 90 days or more or a complete or partial response. Median progression free survival is 82 days. All patients at this dose level are now off-study. Data are maturing for both the 60 and 75 mg/m2 cohorts. One complete response and three partial responses of thirty-four patients for whom data are available are reported thus far at 60 mg/m2; nine patients remain on study. Early response data on ten patients at 75 mg/m2 show one partial response to date and five patients with stable disease; twenty patients remain on study. Voreloxin was generally well-tolerated at 48 and 60 mg/m2, with an incidence of febrile neutropenia of below 10%. An increase in febrile neutropenia is observed at 75 mg/m2, although the incidence remains below 20%.

About Voreloxin

Voreloxin is a novel naphthyridine analog, structurally related to quinolones, a class of compounds that has not been used previously for the treatment of cancer. Voreloxin both intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent, site-sele
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Sunesis to Present at Upcoming Conferences
2. Sunesis to Present at Upcoming Conferences
3. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
4. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
5. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
6. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
7. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
8. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
9. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
10. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
11. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... patient has sepsis, a life-threatening condition in which bacteria ... too fast for antibiotics to help. A new device ... team at Harvard,s Wyss Institute for Biologically Inspired Engineering ... , "Even with the best current treatments, sepsis patients ... percent of the time," said Mike Super, Ph.D., Senior ...
(Date:9/15/2014)... 2014 Zymo Research Corp., has announced the ... safe ambient temperature storage and transport of infectious ... of agents in such samples is completely inactivated ... the viral nucleic acids for subsequent analyses.  With ... in West Africa and ...
(Date:9/15/2014)... 2014 Applied Silicone Corporation, a ... the medical device and critical healthcare market, introduces ... implantable medical device market. The Dual Matrix ... a silicone gel with improved fracture resistance, cohesive ... consists of two crosslinked networks working in conjunction ...
(Date:9/15/2014)... 2014  The second annual International Plasma Awareness ... joint initiative of the Plasma Protein Therapeutics Association ... is designed to: , Raise global awareness ... of plasma donors in saving and improving lives ... rare diseases Member companies are planning ...
Breaking Biology Technology:Blood-cleansing biospleen device developed for sepsis therapy 2Blood-cleansing biospleen device developed for sepsis therapy 3Blood-cleansing biospleen device developed for sepsis therapy 4Safe storage and transport of Ebola, Mers-CoV, and other viruses: Groundbreaking viral inactivation solution capable of preserving nucleic acids 2Safe storage and transport of Ebola, Mers-CoV, and other viruses: Groundbreaking viral inactivation solution capable of preserving nucleic acids 3Applied Silicone Launches Silicone Gel System with Dual Matrix Technology 2International Plasma Awareness Week To Celebrate Donors And Spotlight Rare Diseases 2International Plasma Awareness Week To Celebrate Donors And Spotlight Rare Diseases 3
... SEATTLE, Sept. 26 Today at the ... introduction of a,ground-breaking vaccine to eliminate epidemic ... conjugate vaccine, developed by the Meningitis,Vaccine Project, ... and,PATH and produced by Serum Institute of ...
... in Cancer is Published in the ... of the National Academy of Sciences, MOUNTAIN VIEW, ... focused on discovering, developing,and commercializing therapeutics that target the ... series of rigorous experiments to,elucidate CXCR7,s essential role in ...
... Oxford Finance Corporation,one of the nation,s leading providers ... announced it has finalized a $7 million secured ... will be used,to support Othera,s goal to become ... formulations for,ophthalmology, oncology and inflammatory disease. "This ...
Cached Biology Technology:PATH, World Health Organization, and Partners Introduce Meningitis Vaccine in Burkina Faso 2PATH, World Health Organization, and Partners Introduce Meningitis Vaccine in Burkina Faso 3ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth 2ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth 3ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth 4ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth 5Oxford Finance Corporation Closes $7 Million Debt Facility with Othera Pharmaceuticals 2
(Date:9/15/2014)... Mass. (September 15, 2014) The so-called central ... makes proteinhas long provided a simplified explanation for ... living organisms. , In reality, of course, ... schema first articulated nearly 60 years ago by ... double-helix structure. For one, there are multiple types ...
(Date:9/15/2014)... has evolved a simple, mechanical solution to avoid ... 11 Science Express. , ... misalignments that lead to infertility, miscarriage, or congenital ... cause these problems, but what exactly goes wrong ... the Wellcome Trust Center for Cell Biology at ...
(Date:9/15/2014)... that a single group of microorganisms may be responsible ... the oceans, with implications for the global carbon cycle ... essential molecule required by most life on this planet, ... of microorganisms because it is so large and complex. ... maintaining the brain and nervous systems, as well as ...
Breaking Biology News(10 mins):Scientists discover RNA modifications in some unexpected places 2Cells simply avoid chromosome confusion 2Cells simply avoid chromosome confusion 3Researchers discover new producer of crucial vitamin 2
... also available in Spanish . , ... of Experimental Sciences of the University of ... this reason, immigrant teenagers have a lower probability of suffering ... eating habits. The study has not only analysed for the ...
... of UAB geneticists, doctors and biostatisticians has received $5.7 ... and test new treatments for neurofibromatosis, or NF. ... group called the NF Consortium. The coalition formed more ... clinical trials held across the nation looking at new ...
... the plot to blow up trans-Atlantic airlines with liquid explosives ... pressure on the airline industry, and Homeland Security, to find ... on airline passengers, but also to figure out what they ... Directorate (S&T) is teaming with scientists at the Los Alamos ...
Cached Biology News:Study reveals that immigrant teenagers eat better than Spanish teenagers 2UAB wins $5.7M neurofibromatosis grant 2UAB wins $5.7M neurofibromatosis grant 3Menace in a bottle 2
Abgene's ALTO-8 is the first automated decapper/capper for Abgene Twist-Lock tubes....
... X-Gal (5-bromo-4-chloro-3-indoyl-beta-D-galactopyranoside) is ... to identify recombinant plasmids. ... X-Gal and IPTG, ... appear blue, whereas recombinant ...
... Jouan B4i ventilated and BR4i refrigerated multifunction centrifuges ... speed operation at a low sound level with ... for biocontainment. Their AUTO-LOCK rotor exchange system without ... for use within seconds. Instant rotor ...
... III RNase H- Reverse ... improved version of SuperScript™ ... Like SuperScript™ II it ... strand from single-stranded RNA ...
Biology Products: